| End of treatment (12 months post randomisation) | Follow-up (18 months post randomisation) | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
 | Group | Observed: n (%) | Mean Change (95% CI) | Test | Standardised Coefficient | 12m Predicted Mean (95% CI) | Observed: n (%) | Mean Change (95% CI) | Test | Standardised Coefficientb | 18 m predicted mean (95% CI) |
%mBMI Baseline = 77.95 | FT-AN | 72 (88%) | 10.84 (8.64, 13.04) | t = 9.66 p < 0.001 | 1.79 | 88.78 (86.59, 90.98) | 55 (67%) | 9.63 (7.18, 12.08) | t = 7.71 p < 0.001 | 1.59 | 87.58 (85.13, 90.03) |
 | MFT-AN | 75 (88%) | 13.08 (10.98, 15.18) | t = 12.22 p < 0.001 | 2.16 | 91.03 (88.94, 91.13) | 60 (71%) | 13.74 (11.41, 16.08) | t = 11.53 p < 0.001 | 2.27 | 91.68 (89.33, 94.03) |
BMI Baseline = 15.7 | FT-AN | 72 (88%) | 2.61 (2.16, 3.06) | t = 11.31 p < 0.001 | 2.09 | 18.31 (17.86, 18.76) | 55 (67%) | 2.59 (2.10, 3.08) | t =10.39 p < 0.001 | 2.07 | 18.29 (17.80, 18.78) |
 | MFT-AN | 75 (88%) | 3.01 (2.59, 3.42) | t =14.14 p < 0.001 | 2.41 | 18.71 (18.29, 19.12) | 60 (71%) | 3.33 (2.87, 3.79) | t = 14.24 p < 0.001 | 2.66 | 19.03 (18.57, 19.49) |
EDE (restraint) Baseline = 2.78 | FT-AN | 38 (46%) | −1.38 (−1.90, −0.86) | t = −5.23 p < 0.001 | −0.80 | 1.39 (0.88, 1.92) | 32 (39%) | −1.59 (−2.12 −1.04) | t = −5.77 p < 0.001 | −0.91 | 1.20 (0.66, 1.74) |
 | MFT-AN | 44 (52%) | −0.93 (−1.42 −0.44) | t = −3.76 p = 0.005 | −0.52 | 1.85 (1.36, 2.34) | 38 (45%) | −1.14 (−1.64 −0.63) | t = −4.45 p < 0.001 | −0.75 | 1.64 (1.14, 2.15) |
EDE (eating concerns) Baseline = 2.01 | FT-AN | 38 (46%) | −0.83 (−1.30 −0.35) | t = −3.46 p < 0.001 | −0.54 | 1.18 (0.71, 1.65) | 32 (39%) | −1.10 (−1.57 −0.64) | t = −4.25 p < 0.001 | −0.72 | 0.91 (0.44, 1.37) |
 | MFT-AN | 44 (52%) | −0.70 (−1.13 −0.25) | t = −3.10 p = 0.002 | −0.45 | 1.32 (0.88, 1.76) | 38 (45%) | −0.92 (−1.35 −0.50) | t = −4.25 p < 0.001 | −0.605 | 1.09 (0.66, 1.51) |
EDE (shape concerns) Baseline = 1.83 | FT-AN | 37 (45%) | −1.28 (−1.85 −0.71) | t = −4.44 p < 0.001 | −0.70 | 1.75 (1.18, 2.32) | 32 (39%) | −1.25 (−1.84 −0.66) | t = −4.16 p < 0.001 | −0.68 | 1.78 (1.19, 2.37) |
 | MFT-AN | 44 (52%) | −0.74 (−1.28 −0.20) | t = −2.70 p = 0.0072 | −0.41 | 2.29 (1.75, 2.82) | 38 (45%) | −0.69 (−1.24 −0.15) | t = −2.491 p < 0.013 | −0.38 | 2.34 (1.79, 2.88) |
EDE (weight concerns) Baseline = 2.64 | FT-AN | 38 (46%) | −1.03 (−1.57 −0.48) | t = −3.67 p < 0.001 | −0.54 | 1.62 (1.07, 2.16) | 31 (38%) | −0.88 (−1.50 −0.26) | t = −2.80 p = 0.006 | −0.47 | 1.76 (1.14, 2.38) |
 | MFT-AN | 44 (52%) | −0.59 (−1.12 −0.06) | t = −2.18 p = 0.029 | −0.31 | 2.05 (1.52, 2.58) | 37 (44%) | −0.39 (−0.96, 0.18) | t = −1.34 p = 0.181 | −0.21 | 2.25 (1.68, 2.82) |
BDI Baseline = 24.47 | FT-AN | 35 (43%) | −8.82 (−13.31 −4.33) | t = −3.86 p < 0.001 | −0.62 | 15.65 (11.2, 20.14) | 37 (45%) | −7.40 (−12.04 −2.75) | t = - 3.13 p = 0.002 | −0.52 | 17.07 (12.43, 21.72) |
 | MFT-AN | 41 (48%) | −5.91 (−10.20 −1.63 | t = −2.71 p = 0.007 | −0.41 | 18.55 (14.27, 22.84) | 33 (39%) | −5.26 (−9.89 −0.62) | t = −2.23 p = 0.026 | −0.37 | 19.22 (14.6, 23.85) |
RSE Baseline = 25.68 | FT-AN | 36 (44%) | −0.51 (-2.74, 1.72) | t = −0.45 p = 0.653 | –0.08 | 25.19 (22.96, 27.42) | 37 (45%) | –1.50 (–3.80, 0.79) | t = –1.29 p = 0.199 | –0.51 | 24.20 (21.90, 26.49) |
 | MFT-AN | 42 (49%) | –1.60 (–3.65, 0.44) | t =–1.54 p = 0.124 | –0.24 | 24.10 (22.05, 26.14) | 35 (41%) | –1.00 (–3.11, 1.11) | t = –0.93 p = 0.352 | –0.15 | 24.70 (22.58, 26.18) |
ECI (Negative) Baseline = 85.56 | FT-AN | 44 (54%) | –13.59 (–24.58,–2.59) | t = −2.47 p = 0.016 | −0.45 | 71.97 (60.98, 82.97) |  |  |  |  |  |
 | MFT-AN | 44 (52%) | −15.81 (−26.88 −4.72) | t = −2.86 p = 0.006 | −0.52 | 69.75 (58.68, 80.83) |  |  |  |  |  |
ECI (Positive) Baseline = 28.27 | FT-AN | 47 (57%) | 0.42 (−1.61, 2.45) | t−0.41 p = 0.682 | 0.05 | 28.67 (26.66, 30.72) |  |  |  |  |  |
 | MFT-AN | 46 (54%) | 1.13 (−0.99, 3.25) | t−1.07 p = 0.291 | 0.13 | 29.40 (27.28, 31.52) |  |  |  |  |  |